Jun 06, 2023 / 04:20PM GMT
Matthew Christopher Phipps - William Blair & Company L.L.C., Research Division - Senior Biotechnology Research Analyst
Hi, everyone. My name is Matt Phipps. I'm a biotech analyst here at William Blair, covering Incyte. Happy to have them here at our 43rd Annual Growth Stock Conference. Obviously, first and foremost, please visit williamblair.com for any and all disclosures. But we have Herve Hoppenot, the CEO and Chairman of Incyte, that will give us a presentation today. I think it's clearly an important time for the company as Jakafi continues to dominate, but now it's definitely always a question of what's next. Opzelura is launching well, but I hope to see that continue to grow. So we'll hear about that and some more things in the pipeline today.
So Herve, I'll turn it over to you.
Herve Hoppenot - Incyte Corporation - Chairman, President & CEO
Okay. Maybe I will stand, in fact, that would be working better. So thank you for inviting us to present about Incyte. So I will go through a few slides trying to give you the perspective. It's a
Incyte Corp at William Blair Growth Stock Conference Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers